Englander Institute for Precision Medicine

19q13 amplification with AKT2 and ERCC2 gains in sarcomatoid carcinoma of the urinary bladder.

Title19q13 amplification with AKT2 and ERCC2 gains in sarcomatoid carcinoma of the urinary bladder.
Publication TypeJournal Article
Year of Publication2026
AuthorsMorris G, Vlachostergios PJ, Rai MP, Scherr D, Molina A, Elemento O, Mosquera JMiguel, Cheng L, Faltas BM
JournalCancer Genet
Volume304-305
Pagination51-57
Date Published2026 Mar 10
ISSN2210-7762
Abstract

BACKGROUND: Sarcomatoid carcinoma of the bladder is a rare and aggressive biphasic malignant neoplasm, representing approximately 0.1-0.3% of all bladder cancers. It is characterized by the coexistence of malignant epithelial and mesenchymal components. Its poor prognosis and limited systemic treatment options underscore the need for improved molecular characterization.

CASE PRESENTATION: A 75-year-old male with chronic cystitis and squamous metaplasia of the bladder presented with acute urinary obstruction caused by a large bladder mass. Histopathological evaluation revealed a biphasic tumor with rhabdomyosarcomatous and adenocarcinomatous components. Following radical cystoprostatectomy (pT2a pN0 cM0), whole-exome sequencing (WES) using the EXaCT-1 pipeline identified amplification of the 19q13 locus, including copy-number gains in AKT2 and ERCC2. Nine months postoperatively, the patient developed metastatic recurrence.

CONCLUSIONS: This case contributes to the molecular characterization of bladder sarcomatoid carcinoma through WES. The 19q13 amplification with AKT2 and ERCC2 copy-number gains represents a hypothesis-generating finding that warrants further investigation in larger cohorts.

DOI10.1016/j.cancergen.2026.03.001
Alternate JournalCancer Genet
PubMed ID41880698

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021